BRIEF published on 03/11/2026 at 18:35, 7 months 26 days ago Inoviem Scientific Advances Drug Development with Patient-Centric Approach Personalized Medicine Pharmaceutical Innovation Inoviem Scientific Patient-centric Drug Development Preclinical Programs
PRESS RELEASE published on 03/11/2026 at 18:30, 7 months 26 days ago ATON: UPDATE ON THE ACTIVITIES OF ITS SUBSIDIARY INOVIEM SCIENTIFIC Aton Group's subsidiary, Inoviem Scientific, transforms drug development by prioritizing patient samples & AI technology, accelerating preclinical programs with high-value translational data AI Technology Drug Development Inoviem Scientific Aton Group Patient Sample
BRIEF published on 03/11/2026 at 18:20, 7 months 26 days ago Inoviem Scientific: Advances in Pharmaceutical Development Personalized Medicine Pharmaceutical Development Translational Pharmacology Inoviem Scientific Integrated Platform
BRIEF published on 02/18/2026 at 18:35, 8 months 16 days ago Hadrien Lanvin Appointed Deputy CEO of Aton Group Biotechnology Strategic Growth Deputy CEO Hadrien Lanvin Aton Group
BRIEF published on 02/18/2026 at 18:35, 8 months 16 days ago Hadrien Lanvin appointed Deputy Managing Director of the Aton Group Biotechnology Life Sciences Appointment Hadrien Lanvin Aton Group
PRESS RELEASE published on 02/18/2026 at 18:30, 8 months 16 days ago ATON APPOINTS HADRIEN LANVIN AS DEPUTY CEO Aton Group appoints Hadrien Lanvin as Deputy CEO to drive value and visibility, strengthening leadership and strategic positioning. Focus on maximizing asset portfolio valuation and accelerating development Valuation Leadership Deputy CEO Hadrien Lanvin Aton Group
BRIEF published on 10/31/2025 at 18:05, 1 year ago 2025 Half-Year Results: Aton Confirms its Recovery Financial Recovery 2025 Results PIMS Technology Inoviem Scientific B Cell Design
BRIEF published on 10/08/2025 at 18:05, 1 year ago Strategic partnership between Inoviem Scientific and abc biopply in preclinical oncology Strategic Partnership 3D Models Therapeutic Innovation Preclinical Oncology Translational Pharmacology
BRIEF published on 09/29/2025 at 08:05, 1 year 1 month ago ATON Presents its New Strategy at the European MidCap Event 2025 Investors Governance Financial Strategy Aton European MidCap
BRIEF published on 09/17/2025 at 18:05, 1 year 1 month ago PIMS Technology secures €500,000 in funding from Bpifrance Funding Marketing Precision Medicine Bpifrance PIMS Technology
Published on 11/06/2026 at 22:15, 19 hours 56 minutes ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 1 day 5 hours ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 1 day 5 hours ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 1 day 5 hours ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/07/2026 at 13:35, 4 hours 36 minutes ago Eurobattery Minerals board member and CEO remanded in custody in Sweden
Published on 11/06/2026 at 20:15, 21 hours 56 minutes ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 19:15, 22 hours 56 minutes ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA suspends the interest payment on the bond 2024/2029 due on 8 November 2026.
Published on 11/06/2026 at 19:00, 23 hours 11 minutes ago Finexity AG: FINEXITY issues 2026/2030 bond with a minimum of 7.00% p.a. – either conventionally in a securities account or as a crypto security in a wallet
Published on 11/06/2026 at 18:32, 23 hours 39 minutes ago EQS-Adhoc: Finexity AG: FINEXITY issues 2026/2030 bond
Published on 11/06/2026 at 17:54, 1 day ago Disclosure of Share Capital and Voting Rights as of October 31, 2026
Published on 11/06/2026 at 17:35, 1 day ago Disclosure of the number of shares and the total number of voting rights as of October 31, 2026
